iLux Treatment for Meibomian Gland Dysfunction (MGD)

Evaporative Dry Eye Clinical Trial

Official title:

iLux Treatment for Meibomian Gland Dysfunction (MGD)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03055650
• Other study ID #: 2020-01
• Status: Completed
• Phase: N/A
• Start date: December 7, 2015
• Est. completion date: February 18, 2016

Study information

• Verified date: October 2020
• Source: Tear Film Innovations, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess changes in meibomian gland function and evaporative dry eye symptoms after treatment with the iLux medical device.

Description:

Alcon Research, LLC, acquired TearFilm Innovations, Inc., in December 2018. This study was designed and conducted by TearFilm Innovations, Inc. The study results were collected, analyzed, and provided by TearFilm Innovations, Inc., to Alcon Research, LLC.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: February 18, 2016
• Est. primary completion date: February 18, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age 18 years and older of any gender or race

2. Provision of written informed consent prior to study participation

3. Willingness and ability to return for all study visits

4. A positive history of self-reported dry eye symptoms for three months prior to the study using the Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire, and a score of > 6.

5. Need for regular use of artificial tears, lubricants, or rewetting drops in both eyes

6. Evidence of meibomian gland (MG) obstruction, based on a total meibomian gland secretion score of < 12 out of a maximum score of 45, for 15 glands (5 nasal, 5 medial, 5 temporal) of the lower eyelid of each eye. Glands expressed & graded from 0 to 3 (0 = no secretion, 1 = inspissated, 2 = cloudy, 3 = clear liquid).

Exclusion Criteria:

1. History of ocular surgery including intraocular, oculo-plastic, corneal or refractive surgery within 1 year

2. Ocular trauma or herpetic keratitis within the previous 3 months

3. Cicatricial lid margin disease identified via slit lamp examination, including pemphigoid, symblepharon, etc.

4. Active ocular infection (e.g., viral, bacterial, mycobacterial, protozoan, or fungal infection of the cornea, conjunctiva, lacrimal gland, lacrimal sac, or eyelids including a hordeolum or stye)

5. Active ocular inflammation or history of chronic, recurrent ocular inflammation within prior 3 months (e.g. retinitis, macular inflammation, choroiditis, uveitis, iritis, scleritis, episcleritis, keratitis)

6. Ocular surface abnormality that may compromise corneal integrity (e.g., prior chemical burn, recurrent corneal erosion, corneal epithelial defect, Grade 3 corneal fluorescein staining, or map dot fingerprint dystrophy

7. Lid surface abnormalities (e.g., entropion, ectropion, tumor, edema, blepharospasm, lagophthalmos, severe trichiasis, severe ptosis) that affect lid function in either eye

8. Anterior blepharitis (staphylococcal, demodex or seborrheic grade 3 or 4)

9. Ocular trauma, chemical burns, or limbal stem cell deficiency

10. Systemic disease conditions that cause dry eye (e.g., Stevens-Johnson syndrome, vitamin A deficiency, rheumatoid arthritis, Wegener's granulomatosis, sarcoidosis, leukemia, Riley-Day syndrome, systemic lupus erythematosus, Sjogren's syndrome)

11. Women who are pregnant, nursing, or not utilizing adequate birth control measures

12. Individuals who have either changed the dosing of systemic or ophthalmic medication within the past 30 days prior to screening or who are unable or unwilling to remain on a stable dosing regimen for the duration of the study

13. Individuals using isotretinoin (Accutane) within 1 year, cyclosporine-A (Restasis) within 2 months, or topical medications other than non-preserved artificial tears within 2 weeks.

14. Individuals using another investigational device or agent within 30 days of study participation

15. Contact lens wearers or individuals who have worn contact lenses in the last 30 days or anticipate wearing contact lenses during this study.

Related Conditions & MeSH terms

• Dry Eye Syndromes
• Evaporative Dry Eye
• Keratoconjunctivitis Sicca

Intervention

Device:
• iLux 2020 System
Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands

Locations

Country	Name	City	State
United States	TearFilm Investigative Site	Encinitas	California
United States	TearFilm Investigative Site	San Diego	California
United States	TearFilm Investigative Site	San Diego	California

Sponsors (1)

Lead Sponsor	Collaborator
Tear Film Innovations, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Meibomian Gland Secretion (MGS) Total Score	Meibomian glands on the lower eyelid were assessed by the examiner using a Meibomian Gland Evaluator (MGE 1000) device while viewing the eyelid margin with a slit lamp microscope. 5 glands in 3 zones (nasal, medial, temporal) were evaluated. Each gland was scored from 0-3, for a resultant overall score of 0-45 for each eye. MGS scoring was as follows: 0 = no secretion (worst), 1 = inspissated, 2 = cloudy, 3 = clear liquid (best). A positive change value indicates an improvement. Eyes were assessed individually.	Baseline (Day 0 pretreatment), Week 1, Month 1
Primary	Change From Baseline in Tear Break-Up Time (TBUT)	The investigator instilled a drop of fluorescein into the lower eyelid and asked the patient to blink several times, then stop. The time between the last blink and the first appearance of a dark spot on the cornea (formation of a dry area) on the otherwise continuously stained tear film was recorded in seconds. 3 consecutive measurements were taken, with TBUT defined as the average of the 3 measurements. A positive change value represents A positive change value represents a more stable tear film (improvement). Eyes were assessed individually.	Baseline (Day 0 pretreatment), Week 1, Month 1
Secondary	Change From Baseline in Standard Patient Evaluation of Eye Dryness (SPEED) Total Score	The Standard Patient Evaluation of Eye Dryness (SPEED) survey is a validated survey that assesses both the frequency and severity of dry eye symptoms. The patient grades the frequency of symptoms (4 items) on a scale from 0 to 3 (0=never; 3=constant) and the severity of each symptom (4 items) on a scale from 0 to 4 (0=no problems; 4=intolerable). Responses to the 8 items are summed to calculate a total score ranging from 0 to 28, where 0=best and 28=worst. A negative change value indicates a perceived improvement in ocular health. Both eyes contributed to the mean.	Baseline (Day 0 pretreatment), Week 1, Month 1
Secondary	Change From Baseline in Ocular Surface Disease Index (OSDI) Total Score	The OSDI is a validated, 12-item questionnaire used to measure ocular symptoms, visual function, and environmental factors that may affect a patient's vision. The patient grades each item on a scale from 0 to 4, where 0 is "None" and 4 is "All of the Time." Responses to the 12 items are summed, and a formula is used to calculate a total score from 0 to 100, where 0 corresponds to no disability and 100 corresponds to complete disability. A negative change value represents a perceived improvement in ocular health. Both eyes contributed to the mean.	Baseline (Day 0 pretreatment), Month 1